Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particu...
Saved in:
Main Authors: | Grace Xiong, BHSc, Eric Yu, Martin Heung, Jaehyeong Yang, BSc, Megan Lowe, MPH, Mohannad Abu-Hilal, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-04-01
|
Series: | JAAD International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328724001871 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
by: Pawan Kumar Singh, et al.
Published: (2023-07-01) -
Refractory pityriasis rubra pilaris treated with abrocitinib
by: Filip Rob
Published: (2025-01-01) -
Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01) -
Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis
by: Bai-lin Chen, et al.
Published: (2024-12-01) -
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
by: Liu J, et al.
Published: (2025-02-01)